Text Size
60 studies found for:    plx4032

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Vemurafenib (All Groups);   Drug: Vemurafenib (Post Surgery) - Group A + C;   Other: Post Surgery - Group B
2 Recruiting Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Conditions: Advanced Cancer;   Solid Tumor
Interventions: Drug: Vemurafenib;   Drug: Everolimus;   Drug: Temsirolimus
3 Not yet recruiting Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab
4 Recruiting Vemurafenib and Sorafenib in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Sorafenib
5 Not yet recruiting Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Condition: Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Intervention: Drug: Vemurafenib
6 Recruiting The Effects of Vemurafenib on Immunity in Patients With Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib
7 Recruiting Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Cetuximab;   Drug: Irinotecan
8 Recruiting BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Vemurafenib
9 Recruiting Study of Vemurafenib, Carboplatin, and Paclitaxel
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Carboplatin;   Drug: Paclitaxel
10 Recruiting An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Condition: Neoplasms
Intervention: Drug: vemurafenib
11 Not yet recruiting Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Drug: vemurafenib;   Other: laboratory biomarker analysis
12 Recruiting Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Condition: Advanced BRAF-mutant Cancers
Intervention: Drug: PX-866 in combination with vemurafenib
13 Terminated Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Condition: Melanoma
Intervention: Drug: vemurafenib
14 Not yet recruiting A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Conditions: V600-mutated BRAF Unresectable Melanoma;   V600-mutated BRAF Metastatic Melanoma;   Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Interventions: Drug: PLX3397;   Drug: vemurafenib
15 Recruiting BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
Condition: BRAF Mutant Metastatic Melanoma
Intervention: Drug: BKM120 Combined with Vemurafenib (PLX4032)
16 Recruiting Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Biological: Vemurafenib
17 Recruiting A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: vemurafenib;   Drug: Placebo;   Drug: GDC-0973
18 Recruiting Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Condition: Melanoma
Interventions: Drug: XL888;   Drug: Vemurafenib
19 Recruiting Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Leflunomide
20 Recruiting A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: MPDL3280A;   Drug: Vemurafenib (Zelboraf®)
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years